1 not yet recruiting, 1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Waldenstrom's Macroglobulinaemia Refractory: new trials by email Literature Review of Waldenstrom's Macroglobulinaemia Refractory trials Research Report on Waldenstrom's Macroglobulinaemia Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia Venetoclax - Waldenstrom's Macroglobulinaemia Refractory | Unknown | Poitiers University Hospital | 45 | 2023-12-28 | 2024-01-10 |
Waldenstrom Macroglobulinemia (1)
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
CLR1404 (1) · Dexamethasone (1) · Rituximab (1) · venetoclax (1)
Cellectar Biosciences, Inc. (1) · Poitiers University Hospital (1)
France (1)